FDA Publishes Final PCAC Peptide Briefing Documents on or Around Tuesday July 21 (Two Business Days Before the Thursday July 23 Meeting Opens): The Career-Staff Documents Released June 29-30 and Now Formally Posted for Public Access Recommend Against Adding Any of the Seven Peptides (BPC-157, KPV, TB-500, MOTS-c, DSIP/Emideltide, Semax, Epitalon) to the 503A Bulks List, Citing Immunogenicity Adverse Events, Heavy-Metal and Microbial Contamination in Compounding-Channel Samples, Mislabeled Contents, and Thin 503A Historical Use
The FDA published the final Pharmacy Compounding Advisory Committee briefing documents for the July 23-24 peptide meeting on or around Tuesday July 21, 2026, matching the agency's policy of making advisory-committee briefing documents public no later than two business days before the meeting. The seven career-staff briefing documents (one per peptide: BPC-157, KPV, TB-500, MOTS-c, DSIP/Emideltide, Semax, Epitalon) had already been publicly released in interim form on June 29-30, 2026 and became widely covered mainstream news through the July NPR feature, the Washington Post 'peptide showdown' Health Brief, and the STAT News reporting on panel-composition conflicts. The finalized documents formally posted to the docket recommend against adding any of the seven peptides to the 503A Bulks List, citing immunogenicity adverse events, heavy-metal and microbial contamination in samples pulled from the compounding channel, mislabeled contents, and thin 503A historical use as the specific evidence gaps that prevent bulks-list inclusion. Publication of the final briefing documents means PCAC panelists have their complete reading package and the seven substance-specific evidence maps are the record they will deliberate against during the Thursday-Friday vote.